Outline of presentation

- EDCs – from 1991 to 1996 – Wingspread and Our Stolen Future
- 1996 – FQPA and SDWA mandates endocrine screening
- 1996-1998 – EDSTAC (the assays, debates over modes of action included)
- The final battery – EAT in vivo and in vitro
- The next – 15 years and a significant increase in the database on effects of EDCs in EDSP assays and assay validation
- Implementation on the first round of chemicals
- Cautions on interpretation of Tier 1 Screening data and recommendations for data interpretation of the data.
- Recommendations of structuring Tier 1 screening assays on a decision-logic-tree basis with two in vivo assays as the "Gatekeepers"
- Description of the value of Tier 1.5 before going to Tier 2 testing.
- Using the information from Tier 1 Screening to tailor/enhance Tier 2 testing by adding additional endpoints sensitive to specific modes of endocrine action
- What are the endpoints sensitive to disruption that are not specifically included in tier 2 testing?
- What is the shape of the dose response curve for EDCs in the low dose range for these sensitive endpoints - where dose it matter: In tier 1 or Tier 2?